SCHEMBL2305752

SCHEMBL2305752

O=C1NCCN1c1ccc(S(=O)(=O)Oc2ccccc2I)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.39
CYP1A1 P04798 2/20 0.36
SCN9A Q15858 1/20 0.36
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 4/20 0.35
HTR6 P50406 3/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
EIF2AK2 P19525 1/20 0.34
HSD11B1 P28845 1/20 0.34
HSD17B3 P37058 1/20 0.34
METAP2 P50579 1/20 0.34
METAP1 P53582 1/20 0.34
PARL Q9H300 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2298515 0.85 POLB (0.40) L3MBTL1CYP1A1SCN9AMEN1KMT2A
SCHEMBL2303210 0.85 ALDH1A1 (0.48) L3MBTL1CYP1A1ALDH1A1MAPT
SCHEMBL12353646 0.85 LMNA (0.41) L3MBTL1SCN9AMEN1KMT2AALDH1A1
SCHEMBL2304331 0.85 L3MBTL1 (0.39) L3MBTL1SCN9AMEN1KMT2APOLB
SCHEMBL2305210 0.82 DHODH (0.47) L3MBTL1CYP1A1MEN1KMT2AALDH1A1
SCHEMBL14238623 0.82 L3MBTL1 (0.38) L3MBTL1CYP1A1SCN9AMEN1KMT2A
SCHEMBL2305423 0.82 KMT2A (0.42) L3MBTL1MEN1KMT2AALDH1A1NPC1
SCHEMBL2303163 0.81 SMN1; SMN2 (0.43) L3MBTL1CYP1A1MEN1KMT2AALDH1A1
SCHEMBL2303929 0.81 ALDH1A1 (0.48) CYP1A1MEN1KMT2AALDH1A1HTR6
SCHEMBL2302840 0.80 HTR6 (0.45) CYP1A1MEN1KMT2AALDH1A1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 L3MBTL1 1374/4885CYP1A1 1777/4885SCN9A 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.